Key Takeaways
- Targeted IL-23 Inhibition: Skyrizi (risankizumab) is a humanized monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23), a primary driver of chronic intestinal inflammation.
- INSPIRE Trial Results: In the phase 3 INSPIRE induction study, 20.3% of risankizumab-treated UC patients achieved clinical remission at week 12 versus 6.2% on placebo, with 36.5% achieving endoscopic mucosal improvement.
- Rapid Early Response: Over 52% of risankizumab-treated patients demonstrated clinical response by week 4 of induction.
- Favorable Safety Profile: Common side effects include upper respiratory tract infections, headache, joint pain, injection-site reactions, and fatigue, with a low incidence of serious systemic adverse events.
- Route of Administration: IV induction infusions followed by subcutaneous maintenance injections.
How Skyrizi Works: Selective IL-23 p19 Inhibition
Interleukin-23 (IL-23) plays a critical role in sustaining chronic autoimmune inflammation in the intestinal mucosa:
- Targeting p19: Risankizumab specifically binds to the p19 subunit of IL-23, neutralizing its interaction with cell-surface receptors.
- Sparing IL-12: Unlike dual IL-12/23 inhibitors (such as Stelara / ustekinumab), Skyrizi selectively inhibits IL-23 without blocking IL-12, preserving key host defense signaling pathways.
- Reducing Pathogenic T-Cells: Inhibits Th17 cell proliferation and suppresses downstream production of inflammatory cytokines (IL-17, IL-22, TNF).
Clinical Trial Efficacy in Ulcerative Colitis (INSPIRE)
In the landmark phase 3 INSPIRE induction trial evaluating risankizumab in adults with moderate to severe active ulcerative colitis:
- Week 12 Clinical Remission: 20.3% on risankizumab vs. 6.2% on placebo.
- Week 4 Early Response: 52.2% on risankizumab vs. 30.5% on placebo.
- Week 12 Clinical Response: 64.3% on risankizumab vs. 35.7% on placebo.
- Endoscopic Improvement: 36.5% vs. 12.1% on placebo.
- Histologic-Endoscopic Remission: Statistically significant higher rates of deep tissue healing compared to placebo.
Efficacy was demonstrated both in bio-naïve patients and in those who had previously failed anti-TNF biologics, integrin inhibitors, or JAK inhibitors.
Side Effects & Safety Profile
Across extensive clinical trials in psoriasis, Crohn’s disease, and ulcerative colitis, Skyrizi exhibits a favorable safety and tolerability profile:
Common Side Effects
- Upper respiratory infections (colds, sinus infections, pharyngitis)
- Headache and fatigue
- Arthralgia (joint pain)
- Injection-site reactions (redness, pain, swelling)
- Mild fungal skin infections and rash
Serious Risks & Monitoring
- Serious Infections: As with all biologic therapies, Skyrizi increases infection risk. Pre-treatment tuberculosis (TB) screening and periodic infection monitoring are required.
- Hypersensitivity: Rare severe allergic reactions or anaphylaxis.
- Malignancy & Cardiovascular Safety: Clinical trial registries have shown no elevated signal for malignancy or major adverse cardiovascular events (MACE) compared to control populations.
Where Skyrizi Fits in the UC Treatment Landscape
IL-23 p19 inhibitors represent a major therapeutic advancement for ulcerative colitis management:
- Ideal Option for Biologic-Experienced Patients: Highly effective for patients who have lost response or experienced side effects on anti-TNFs (Humira, Remicade).
- Targeted Mechanism: Offers strong endoscopic healing outcomes with a clean systemic safety profile.
- Convenient Subcutaneous Maintenance: Allows home self-administration following initial hospital-based IV induction infusions.
Related Clinical & Diagnostic Resources
- Entyvio (Vedolizumab) Guide
- Rinvoq (Upadacitinib) Guide
- Anti-Inflammatory Diet Protocol
- Take 60s Gut Trigger Assessment
References
- Louis E, et al. Risankizumab induction therapy in patients with moderate-to-severe ulcerative colitis: Results from the phase 3 INSPIRE trial. J Crohns Colitis. 2024;18(Suppl 1):i1-i3.
- US FDA. Skyrizi (risankizumab-rzaa) Prescribing Information. 2024.
